A snapshot of the work of CDC's Division of Parasitic Diseases and Malaria.

1. Namita Joshi
Deputy Director for Policy and Communications
Division of Parasitic Diseases and Malaria
Center for Global Health
June 2015
CDC’s Malaria Program and Priorities
Division of Parasitic Diseases and Malaria
Center for Global Health

2. Division of Parasitic Diseases and Malaria
•Director:Laurence Slutsker
•Deputy Director for Management & Operations:Eric
Gogstad
•Deputy Director for Program & Science/ADS:Monica
•Parise
•Associate Director for Laboratory Science:Kumar
Udhayakumar
•Associate Director for Policy:Namita Joshi
•Data Management Activity:Ryan Wiegand
Office of the Director
Malaria Branch
•Chief: S.Patrick Kachur
•Manager: Richard Kahn
Parasitic Diseases Branch
•Chief: Stephanie Bialek
•Manager: Hoang Dang
Entomology Branch
•Chief:William Hawley
•Manager: Matthew Stockton
Strategic Applied
Science
Team Lead:
Mary Hamel
Program
Implementation
Team Lead:
Peter McElroy
Domestic
Response
Team Lead:
Paul Arguin
Laboratory
Research &
Development
Team Lead:
John Barnwell
Elimination & Control
Team Lead: Leanne Fox
Epidemiology
Team Lead: Susan Montgomery
Diagnostics & Biology
Team Lead: Vacant
Operations and Vector Genetics
Team Lead: Ellen Dotson
Field Support
Team Lead: John Gimnig
Chemistry & Resistance
Team Lead: Bill Brogdon
2

3. Malaria in the United States
 Malaria vectors —
Anopheles mosquitoes —
are widespread in U.S.
 CDC helps keep the U.S.
safe:
 Advises public how to protect
themselves from malaria
during travel
 Tracks malaria
 Helps clinicians diagnose and
treat malaria cases 24/7
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6312a1.htm
3

4. President’s Malaria Initiative (PMI)
Interagency initiative to reduce illness and death in
high-burden African countries
CDC supports PMI through:
 Scaling up control interventions
 Insecticide-treated nets
 Indoor residual spraying
 Confirmed diagnosis and treatment with
artemisinin combination therapy (ACT)
 Preventive treatment for pregnant women
 Scientific expertise
 Strategic information (surveillance,
research and M&E)
 Diagnosis and treatment
 Prevention
 Laboratory strengthening
4

5. PMI: Scaling up proven tools
Rapid diagnosis and artemisinin-based
combination therapies (ACTs)
Insecticide-treated bed nets
(ITNs)
Intermittent preventive treatment in
pregnancy (IPTp)
Indoor residual spraying (IRS) (where
appropriate)
5

6.  CDC contributed to the development and evaluation of four interventions now
used worldwide.
Malaria interventions save lives
 Challenges to this success include:
 Insecticide treated nets: coverage, durability,insecticide resistance, and
changes in mosquito behavior
 Evidence of artemisinin drug resistance
TOMORROW
Intermittent screen and treat,
mass drug administration,single
encounter radical cure
treatments,transmission
blocking drugs,durable wall
liners,spatial repellents,novel
diagnostics,vaccines
TODAY
Prevention
Insecticide-treated bed
nets,indoor spraying,
preventive treatment
for pregnant women
and infants,seasonal
chemoprevention
TODAY
Treatment
Diagnosis with rapid
tests and combination
treatment,pre-referral
and definitive
treatment of severe
disease
6

7. CDC Malaria Priorities
 Malaria in the U.S.
(monitoring,diagnostics,
clinical guidance,
prevention)
 Accelerate elimination
and control of malaria
 Research
 Elimination
 Parasite,vector,case
management
 What is the right mix?
7

8. Accelerate the Elimination of Malaria
 New WHO Global Technical
Strategy calls for acceleration
towards elimination
 Regional focus for assisting
countries to eliminate malaria
 Hispaniola
 South East Asia
 5 PMI focus countries
 New tools and approaches needed
to support elimination,such as
• strong disease monitoring
system
• diagnostic tools developed for
use in low transmission settings
8

9. CDC’s Scientific Investments in Malaria
Evaluation and
impact of current
interventions
Routine surveillance,
field evaluation of
promising tools &
approaches,
scientific leadership
Basic development
of new drugs,
diagnostics, vector
control paradigms,
vaccines
PMI CDC Applied Science BMGF, NIH
Prevention and Control Elimination/Eradication
9

10. 10
Malaria Science at CDC
Donald Stokes (1997). Pasteur’s Quadrant: Basic science and Technological Innovation. Washington: Brookings Institution Press.
Basic Research
Pure Science
Bohr’s quadrant
Use-inspired Research
Strategic Science
Pasteur’s quadrant
Operations Research
Applied Science
Edison’s quadrant
low Immediate Use Potential high
lowGeneralizability/KnowledgeCreationhigh

11. 11
 Adapting human parasites to laboratory models
 Natural history of malaria infection in highly endemic settings
 Systems effectiveness of artemisinin-based combination treatment
 Efficacy of insecticide-treated nets,malaria vaccine candidates
 Effect of intermittent screening and treatment on transmission
 Identification of new diagnostic targets and approaches
 Evaluation of spatial repellants for malaria prevention
 Parenteral artesunate for severe malaria in North America (IND)
 Durability of long-lasting insecticidal nets in field conditions
 Impact evaluation after scale up of proven malaria control tools
 Cost-effectiveness of universal diagnostic testing in African countries
Malaria Science at CDC: Examples
Pure Science
Applied Science
Strategic Science

12. Research to Support Elimination
 Development of more sensitive diagnostic tests to help detect
persons with low density infections as a way to further reduce
transmission
 Field trials of promising malaria vaccines: RTS,S/AS01 and PfSPZ
 Evaluation of improved nets,new insecticides,novel vector
control paradigms: insecticide treated durable wall liners and
spatial repellants
 Evaluating strategic use of antimalarial drugs administered to
target populations to reduce transmission and burden
 CDC provides global resources through its Collaborating Centers,
world renowned insectary and laboratories
 Research partnerships in the Greater Mekong subRegion,Latin
America,Indonesia,Kenya,Madagascar,Malawi,Tanzania, Uganda
12

13. Drug Quality/Counterfeit Drugs
 Robust sampling methodologies to assess presence of
counterfeits
 Developing rapid field assays
 Evaluation of FDA’s CD3 device and co-inventor of the CD4
 Antimalarial drug analysis activites
 multiple countries completing drug efficacy studies
 Analysis for the Global Health Access Program , on the Thailand-
Burma border
 Analysis of analyzed ACTs acquired by the Global Fund Joint
Inter-Agency Task Force (JIATF)
 Cosponsored an antimalarial drug quality in Africa
symposium at the 6th Multilateral Initiative on Malaria
Pan-African Malaria Congress
13

14. Drugs/Diagnostics/Vector Control
 New and existing malaria drugs for reducing
transmission
 Examples: mass drug administration, mass screen and treat
 Improved diagnostic tests capable of identifying low
levels of infection and transmission.
 ReaLAMP
 Multiplex format
 New tools for vector control,including pesticides and
paradigms for deliver them
 Wall liners,spatial repellants,baited traps
14

15. What More Can Be Done?
 Surveillance as an
intervention
 Moving diagnosis and
treatment beyond case
management
 Development and
deployment of new tools
 Mitigating threats to
continued progress
15

16. For more information please contact Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta,GA 30333
Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
E-mail: cdcinfo@cdc.gov Web: www.cdc.gov
Namita Joshi
ngs5@cdc.gov
www.cdc.gov/malaria
Center for Global Health
Malaria Branch, Division of Parasitic Diseases and Malaria
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Prevention.